An interesting trend is targeting B cell intracellular signaling, such as through inhibition of Bruton's Tyrosine Kinase (BTK), which is a strategy approved for the treatment of B cell malignancies.
← all excerpts
B Cell Therapy in Systemic Lupus Erythematosus: From Rationale to Clinical Practice.
1
—
—